Acadia Pharmaceuticals Stock
Acadia Pharmaceuticals Stock
Acadia Pharmaceuticals shows a slight decrease today, losing -€0.230 (-1.000%) compared to yesterday.
The stock is one of the favorites of our community with 28 Buy predictions and 1 Sell predictions.
With a target price of 29 € there is a positive potential of 29.18% for Acadia Pharmaceuticals compared to the current price of 22.45 €.
Our community identified positive and negative aspects for Acadia Pharmaceuticals stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Acadia Pharmaceuticals stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Acadia Pharmaceuticals in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
B****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Acadia Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Acadia Pharmaceuticals | -1.000% | 2.840% | 1.354% | 7.519% | -3.358% | -16.231% | 23.081% |
| Ligand Pharmaceuticals | -1.540% | -3.759% | -7.246% | 118.803% | 54.217% | 316.260% | 167.056% |
| United Therapeutics | -1.560% | -3.421% | -5.275% | 86.343% | 5.055% | 103.398% | 189.613% |
| Ionis Pharmaceuticals Inc. | -2.030% | -9.692% | -36.406% | 19.220% | -33.917% | 19.125% | 43.391% |
Comments
ACADIA Pharmaceuticals (ACAD) had its price target raised by BMO Capital Markets from $34.00 to $36.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (ACAD) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (ACAD) had its price target raised by Bank of America Corporation from $29.00 to $30.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ACAD provided by MarketBeat